High Estrogen Receptor β Expression Is Prognostic among Adjuvant Chemotherapy-Treated Patients-Results from a Population-Based Breast Cancer Cohort
Elebro, Karin LU ; Borgquist, Signe LU ; Rosendahl, Ann H LU ; Markkula, Andrea LU ; Simonsson, Maria LU ; Jirström, Karin LU
; Rose, Carsten
LU
; Ingvar, Christian
LU
and Jernström, Helena
LU
(2017)
In Clinical Cancer Research
23(3).
p.766-777
- Abstract
PURPOSE: Isoform-specific tumor estrogen receptor β (ERβ) expression may hold prognostic information in breast cancer, especially among endocrine-treated breast cancer patients. The study's purpose was to evaluate ERβ isoform 1 (ERβ1) expression in relation to tumor characteristics, ESR2 genotypes, and prognosis in different treatment groups.
EXPERIMENTAL DESIGN: A population-based prospective cohort of 1,026 patients diagnosed with primary invasive breast cancer in Lund, Sweden, between October 2002 and June 2012 was followed until June 2014 (median 5 years). Associations between immunohistochemical ERβ1 expression, patient and tumor characteristics, as well as outcome within treatment groups were analyzed.
RESULTS: Tumor... (More)
PURPOSE: Isoform-specific tumor estrogen receptor β (ERβ) expression may hold prognostic information in breast cancer, especially among endocrine-treated breast cancer patients. The study's purpose was to evaluate ERβ isoform 1 (ERβ1) expression in relation to tumor characteristics, ESR2 genotypes, and prognosis in different treatment groups.
EXPERIMENTAL DESIGN: A population-based prospective cohort of 1,026 patients diagnosed with primary invasive breast cancer in Lund, Sweden, between October 2002 and June 2012 was followed until June 2014 (median 5 years). Associations between immunohistochemical ERβ1 expression, patient and tumor characteristics, as well as outcome within treatment groups were analyzed.
RESULTS: Tumor ERβ1 expression was available for 911 patients (89%) and was not associated with ESR2 genotypes. ERβ1 positivity, defined as >75% (ERβ175(+), 72.7%), was positively associated with established favorable tumor characteristics. Overall, ERβ175(+) was associated with lower risk of breast cancer events [HRadj = 0.60; 95% confidence interval (CI), 0.41-0.89]. The magnitude of the association was larger in patients with ERα(-) tumors (HRadj = 0.30; 95% CI, 0.12-0.76), compared with ERα(+) tumors (HRadj = 0.66; 95% CI, 0.42-1.03). Among the 232 chemotherapy-treated patients, ERβ175(+) tumors were associated with lower risk of breast cancer events compared with ERβ175(-) tumors (HRadj = 0.31; 95% CI, 0.15-0.64). Among the 671 chemonaïve patients, ERβ175 status was not associated with the outcome.
CONCLUSION: High ERβ1 expression was a favorable prognostic marker in this breast cancer cohort, especially in chemotherapy-treated patients, but not in endocrine therapy-treated patients. These results warrant confirmation, preferably via a biomarker study in a previously conducted randomized trial. Clin Cancer Res; 1-12. ©2016 AACR.
(Less)
- author
- Elebro, Karin
LU
; Borgquist, Signe
LU
; Rosendahl, Ann H
LU
; Markkula, Andrea
LU
; Simonsson, Maria
LU
; Jirström, Karin
LU
; Rose, Carsten
LU
; Ingvar, Christian
LU
and Jernström, Helena
LU
- organization
-
- Breastcancer-genetics
- Tumor microenvironment
- Breast cancer prevention & intervention (research group)
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
- Epidemiology and pharmacogenetics (research group)
- Personalized Pathology & Cancer Therapy (research group)
- Department of Immunotechnology
- Create Health
- Surgery (Lund)
- Lund Melanoma Study Group (research group)
- publishing date
- 2017
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical Cancer Research
- volume
- 23
- issue
- 3
- pages
- 766 - 777
- publisher
- American Association for Cancer Research
- external identifiers
-
- scopus:85012247397
- wos:000393884000017
- pmid:27810901
- ISSN
- 1078-0432
- DOI
- 10.1158/1078-0432.CCR-16-1095
- language
- English
- LU publication?
- yes
- id
- 29a4faca-c095-46c7-8da2-fe344faf84b5
- date added to LUP
- 2017-01-02 11:01:51
- date last changed
- 2024-05-31 20:50:28
@article{29a4faca-c095-46c7-8da2-fe344faf84b5,
abstract = {{<p>PURPOSE: Isoform-specific tumor estrogen receptor β (ERβ) expression may hold prognostic information in breast cancer, especially among endocrine-treated breast cancer patients. The study's purpose was to evaluate ERβ isoform 1 (ERβ1) expression in relation to tumor characteristics, ESR2 genotypes, and prognosis in different treatment groups.</p><p>EXPERIMENTAL DESIGN: A population-based prospective cohort of 1,026 patients diagnosed with primary invasive breast cancer in Lund, Sweden, between October 2002 and June 2012 was followed until June 2014 (median 5 years). Associations between immunohistochemical ERβ1 expression, patient and tumor characteristics, as well as outcome within treatment groups were analyzed.</p><p>RESULTS: Tumor ERβ1 expression was available for 911 patients (89%) and was not associated with ESR2 genotypes. ERβ1 positivity, defined as >75% (ERβ175(+), 72.7%), was positively associated with established favorable tumor characteristics. Overall, ERβ175(+) was associated with lower risk of breast cancer events [HRadj = 0.60; 95% confidence interval (CI), 0.41-0.89]. The magnitude of the association was larger in patients with ERα(-) tumors (HRadj = 0.30; 95% CI, 0.12-0.76), compared with ERα(+) tumors (HRadj = 0.66; 95% CI, 0.42-1.03). Among the 232 chemotherapy-treated patients, ERβ175(+) tumors were associated with lower risk of breast cancer events compared with ERβ175(-) tumors (HRadj = 0.31; 95% CI, 0.15-0.64). Among the 671 chemonaïve patients, ERβ175 status was not associated with the outcome.</p><p>CONCLUSION: High ERβ1 expression was a favorable prognostic marker in this breast cancer cohort, especially in chemotherapy-treated patients, but not in endocrine therapy-treated patients. These results warrant confirmation, preferably via a biomarker study in a previously conducted randomized trial. Clin Cancer Res; 1-12. ©2016 AACR.</p>}},
author = {{Elebro, Karin and Borgquist, Signe and Rosendahl, Ann H and Markkula, Andrea and Simonsson, Maria and Jirström, Karin and Rose, Carsten and Ingvar, Christian and Jernström, Helena}},
issn = {{1078-0432}},
language = {{eng}},
number = {{3}},
pages = {{766--777}},
publisher = {{American Association for Cancer Research}},
series = {{Clinical Cancer Research}},
title = {{High Estrogen Receptor β Expression Is Prognostic among Adjuvant Chemotherapy-Treated Patients-Results from a Population-Based Breast Cancer Cohort}},
url = {{http://dx.doi.org/10.1158/1078-0432.CCR-16-1095}},
doi = {{10.1158/1078-0432.CCR-16-1095}},
volume = {{23}},
year = {{2017}},
}